Hormonal
Antagonism of the growth hormone secretagogue receptor (GHS-R) using specific peptide antagonists reduces food intake, decreases body weight gain, and improves glycaemic control in obese mouse models.
This research suggests that blocking the ghrelin receptor (GHS-R) can reduce food intake and body weight gain in obese individuals. While this specific study used mouse models and peptide antagonists, it supports the biological plausibility that ghrelin signaling plays a key role in obesity and that targeting this pathway could be a valid strategy for weight management and improving blood sugar control.
Repeated administration of GHS-R antagonist decreased body weight gain and improved glycaemic control in ob/ob obese mice.
Why this rating
The study is conducted on mouse models (ob/ob and diet-induced obesity), not humans, limiting direct translatability to human fitness outcomes without further clinical validation.
Source
Antagonism of ghrelin receptor reduces food intake and body weight gain in mice
Akihiro Asakawa et al. · Gut · 2003
DOI 10.1136/gut.52.7.947
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →